271 related articles for article (PubMed ID: 25697710)
1. Multifocal retinopathy in Dachshunds with CLN2 neuronal ceroid lipofuscinosis.
Whiting RE; Pearce JW; Castaner LJ; Jensen CA; Katz RJ; Gilliam DH; Katz ML
Exp Eye Res; 2015 May; 134():123-32. PubMed ID: 25697710
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal gene therapy preserves retinal function in a canine model of CLN2 neuronal ceroid lipofuscinosis.
Kick GR; Whiting REH; Ota-Kuroki J; Castaner LJ; Morgan-Jack B; Sabol JC; Meiman EJ; Ortiz F; Katz ML
Exp Eye Res; 2023 Jan; 226():109344. PubMed ID: 36509165
[TBL] [Abstract][Full Text] [Related]
3. Neuronal ceroid lipofuscinosis type CLN2: a new rationale for the construction of phenotypic subgroups based on a survey of 25 cases in South America.
Kohan R; Carabelos MN; Xin W; Sims K; Guelbert N; Cismondi IA; Pons P; Alonso GI; Troncoso M; Witting S; Pearce DA; Dodelson de Kremer R; Oller-Ramírez AM; Noher de Halac I
Gene; 2013 Mar; 516(1):114-21. PubMed ID: 23266810
[TBL] [Abstract][Full Text] [Related]
4. CLN2 disease resulting from a novel homozygous deep intronic splice variant in TPP1 discovered using long-read sequencing.
Steigerwald C; Borsuk J; Pappas J; Galey M; Scott A; Devaney JM; Miller DE; Abreu NJ
Mol Genet Metab; 2023 Dec; 140(4):107713. PubMed ID: 37922835
[TBL] [Abstract][Full Text] [Related]
5. [Tripeptidyl peptidase 1 deficiency in neuronal ceroid lipofuscinosis. A novel mutation].
Bukina AM; Tsvetkova IV; Semiachkina AN; Il'ina ES
Vopr Med Khim; 2002; 48(6):594-8. PubMed ID: 12698559
[TBL] [Abstract][Full Text] [Related]
6. Mouse gene knockout models for the CLN2 and CLN3 forms of ceroid lipofuscinosis.
Katz ML; Johnson GS
Eur J Paediatr Neurol; 2001; 5 Suppl A():109-14. PubMed ID: 11588979
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of tripeptidyl-peptidase 1 by 3-hydroxy-(2,2)-dimethyl butyrate, a brain endogenous ligand of PPARα: Implications for late-infantile Batten disease therapy.
Chakrabarti S; Chandra S; Roy A; Dasarathi S; Kundu M; Pahan K
Neurobiol Dis; 2019 Jul; 127():362-373. PubMed ID: 30928643
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal enzyme replacement for inherited retinal diseases.
Rodriguez-Martinez AC; Wawrzynski J; Henderson RH
Curr Opin Ophthalmol; 2024 May; 35(3):232-237. PubMed ID: 38170785
[TBL] [Abstract][Full Text] [Related]
9. First in man study of intravitreal tripeptidyl peptidase 1 for CLN2 retinopathy.
Wawrzynski J; Martinez AR; Thompson DA; Ram D; Bowman R; Whiteley R; Gan C; Harding L; Mortensen A; Mills P; Gissen P; Henderson RH
Eye (Lond); 2024 Apr; 38(6):1176-1182. PubMed ID: 38049626
[TBL] [Abstract][Full Text] [Related]
10. A mouse model of classical late-infantile neuronal ceroid lipofuscinosis based on targeted disruption of the CLN2 gene results in a loss of tripeptidyl-peptidase I activity and progressive neurodegeneration.
Sleat DE; Wiseman JA; El-Banna M; Kim KH; Mao Q; Price S; Macauley SL; Sidman RL; Shen MM; Zhao Q; Passini MA; Davidson BL; Stewart GR; Lobel P
J Neurosci; 2004 Oct; 24(41):9117-26. PubMed ID: 15483130
[TBL] [Abstract][Full Text] [Related]
11. Lysosomal protein thermal stability does not correlate with cellular half-life: global observations and a case study of tripeptidyl-peptidase 1.
Collier AM; Nemtsova Y; Kuber N; Banach-Petrosky W; Modak A; Sleat DE; Nanda V; Lobel P
Biochem J; 2020 Feb; 477(3):727-745. PubMed ID: 31957806
[TBL] [Abstract][Full Text] [Related]
12. A needle in a haystack? The impact of a targeted epilepsy gene panel in the identification of a treatable but rapidly progressive metabolic epilepsy: CLN2 disease.
Lourenço CM; Sallum JMF; Pereira AM; Girotto PN; Kok F; Vilela DRF; Barron E; Pessoa A; Oliveira BM
Arq Neuropsiquiatr; 2024 May; 82(5):1-8. PubMed ID: 38763144
[TBL] [Abstract][Full Text] [Related]
13. Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis.
Crystal RG; Sondhi D; Hackett NR; Kaminsky SM; Worgall S; Stieg P; Souweidane M; Hosain S; Heier L; Ballon D; Dinner M; Wisniewski K; Kaplitt M; Greenwald BM; Howell JD; Strybing K; Dyke J; Voss H
Hum Gene Ther; 2004 Nov; 15(11):1131-54. PubMed ID: 15610613
[TBL] [Abstract][Full Text] [Related]
14. Peripheral retinal finding on fluorescein angiography in neuronal ceroid lipofuscinosis type 2 (CLN2).
Rogers DL; De Los Reyes E; Mendel TA; Caprul B; Podlasiak S; Jordan CO
J AAPOS; 2024 Apr; 28(2):103830. PubMed ID: 38341082
[TBL] [Abstract][Full Text] [Related]
15. A Novel Porcine Model of CLN2 Batten Disease that Recapitulates Patient Phenotypes.
Swier VJ; White KA; Johnson TB; Sieren JC; Johnson HJ; Knoernschild K; Wang X; Rohret FA; Rogers CS; Pearce DA; Brudvig JJ; Weimer JM
Neurotherapeutics; 2022 Oct; 19(6):1905-1919. PubMed ID: 36100791
[TBL] [Abstract][Full Text] [Related]
16. An ERG and OCT study of neuronal ceroid lipofuscinosis CLN2 Battens retinopathy.
Thompson DA; Handley SE; Henderson RH; Marmoy OR; Gissen P
Eye (Lond); 2021 Sep; 35(9):2438-2448. PubMed ID: 34272513
[TBL] [Abstract][Full Text] [Related]
17. Biochemical characterization of a lysosomal protease deficient in classical late infantile neuronal ceroid lipofuscinosis (LINCL) and development of an enzyme-based assay for diagnosis and exclusion of LINCL in human specimens and animal models.
Sohar I; Sleat DE; Jadot M; Lobel P
J Neurochem; 1999 Aug; 73(2):700-11. PubMed ID: 10428067
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study.
Schulz A; Specchio N; de Los Reyes E; Gissen P; Nickel M; Trivisano M; Aylward SC; Chakrapani A; Schwering C; Wibbeler E; Westermann LM; Ballon DJ; Dyke JP; Cherukuri A; Bondade S; Slasor P; Cohen Pfeffer J
Lancet Neurol; 2024 Jan; 23(1):60-70. PubMed ID: 38101904
[TBL] [Abstract][Full Text] [Related]
19. Mutations in classical late infantile neuronal ceroid lipofuscinosis disrupt transport of tripeptidyl-peptidase I to lysosomes.
Steinfeld R; Steinke HB; Isbrandt D; Kohlschütter A; Gärtner J
Hum Mol Genet; 2004 Oct; 13(20):2483-91. PubMed ID: 15317752
[TBL] [Abstract][Full Text] [Related]
20. A computational approach to analyzing the functional and structural impacts of Tripeptidyl-Peptidase 1 missense mutations in neuronal ceroid lipofuscinosis.
K P; Madhana PN; Eswaramoorthy R; Ramasamy M
Metab Brain Dis; 2024 Apr; 39(4):545-558. PubMed ID: 38185715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
